Delphix เร่งการเติบโตและความสามารถในการทำกำไรเป็นปีที่สองติดต่อกัน

ความปลอดภัยของข้อมูลและการปฏิบัติตามข้อกำหนดผลักดันให้มีการใช้งานแพลตฟอร์มการจัดการข้อมูลการทดสอบ Delphix DevOps เพิ่มขึ้นอย่างรวดเร็ว

เรดวูดซิตี้ แคลิฟอร์เนีย, April 29, 2022 (GLOBE NEWSWIRE) —  Delphix ผู้นำอุตสาหกรรมในการจัดการข้อมูลการทดสอบ DevOps (TDM) ประกาศปิดปีงบประมาณ 2022 ด้วยการเติบโตของรายได้และความสามารถในการทำกำไรในระดับที่รวดเร็วเป็นปีที่สองติดต่อกัน โดยมีรายได้ประจำประจำปี (ARR) มากกว่า 100 ล้านเหรียญสหรัฐ

ด้วยกิจกรรมที่เพิ่มขึ้นจากประเทศที่เป็นศัตรูและแก๊งแรนซัมแวร์ บริษัทต่าง ๆ ทั่วโลกจึงต้องการโซลูชันในการทำให้ข้อมูลทดสอบเป็นอัตโนมัติและมีการรักษาความปลอดภัยสำหรับแอปพลิเคชันระดับองค์กร ด้วยเหตุนี้ ทำให้บริษัทมีการเติบโตของฐานลูกค้าองค์กรขนาดใหญ่ที่เติบโตเร็วขึ้น 36% เมื่อเทียบเป็นรายปี โดยได้แรงหนุนจากความเสี่ยงด้านข้อมูลที่เพิ่มขึ้น

การเติบโตของ Delphix เกิดขึ้นเนื่องจากบริษัทต่าง ๆ ทั่วโลกยังคงลงทุนในโซลูชัน DevOps ที่เป็นนวัตกรรมใหม่ๆ เพื่อเร่งการส่งมอบแอปพลิเคชัน ปรับปรุงโครงสร้างพื้นฐานแบบเดิมให้ทันสมัย และเคลื่อนย้ายแอปพลิเคชันต่าง ๆ ไปทั่วมัลติคลาวด์ Delphix นำเสนอแพลตฟอร์ม DevOps TDM เพียงแพลตฟอร์มเดียวที่ส่งมอบข้อมูลที่ปลอดภัยและเป็นไปตามข้อกำหนดสำหรับการทดสอบและการพัฒนาโดยอัตโนมัติ ทำให้สามารถสร้างสรรค์นวัตกรรมได้เร็วขึ้นถึง 10 เท่า

Jedidiah Yueh ผู้ก่อตั้งและซีอีโอของ Delphix กล่าวว่า “แอปพลิเคชันระดับองค์กรล้วนต้องการข้อมูลทดสอบเพื่อการเผยแพร่ที่รวดเร็วและมีคุณภาพ” “แต่ปกติแล้วข้อมูลการทดสอบจะช้า ซับซ้อน และเต็มไปด้วยความเสี่ยง Delphix ช่วยให้บริษัทต่างๆ เช่น Banco Carrefour, The University of Manchester และ BNP Paribas เปิดตัวแอปพลิเคชันต่างๆ ได้อย่างรวดเร็ว พร้อมทั้งได้ปรับปรุงความปลอดภัยและการปฏิบัติตามข้อกำหนดของข้อมูลไปด้วยกัน”

Banco Carrefour ในบราซิลใช้แพลตฟอร์มข้อมูล Delphix DevOps เพื่อเร่งการเปิดตัวแอปพลิเคชัน พร้อมทั้งได้มีการรับรองความปลอดภัยของข้อมูลและการปฏิบัติตามกฎระเบียบด้านความเป็นส่วนตัวไปด้วยกัน เช่น กฎหมายคุ้มครองข้อมูลทั่วไปของบราซิล (LGPD) Delphix เพิ่มขีดความสามารถให้ทีมพัฒนาด้วยความพร้อมใช้งานของข้อมูลที่เร็วขึ้นถึง 320 เท่าสำหรับการรายงานและการวิเคราะห์ทางการเงิน ช่วยให้ออกแอปพลิเคชันได้เร็วขึ้น และช่วยประหยัดพื้นที่จัดเก็บได้ถึง 70%

Delphix นำเสนอแพลตฟอร์มข้อมูล API ซึ่งเป็นนวัตกรรมใหม่ที่เปลี่ยนการส่งมอบแอปพลิเคชันด้วยการควบคุมข้อมูลที่ครอบคลุม Delphix ช่วยให้นักพัฒนาซอฟต์แวร์สร้างสรรค์สิ่งใหม่ ๆ ได้เร็วขึ้น ในขณะที่ลดความเสี่ยงในการปฏิบัติตามข้อกำหนดและความปลอดภัย โดยใช้การส่งข้อมูลแบบอัตโนมัติในสภาพแวดล้อมของการทดสอบ

Delphix ยังช่วยให้บริษัทกู้คืนข้อมูลจากการโจมตีของแรนซัมแวร์ได้เร็วขึ้น ด้วยการปกป้องข้อมูลอย่างต่อเนื่องและทำให้ข้อมูลในอดีตไม่เปลี่ยนแปลง

Yves Caseau ประธานเจ้าหน้าที่ฝ่ายดิจิทัลและสารสนเทศของกลุ่มบริษัท Michelin กล่าวว่า “เราเลือก Delphix เพราะเราชอบเทคโนโลยีที่ใช้เป็นเครื่องมือในการย้ายข้อมูลอย่างมีประสิทธิภาพจากที่หนึ่งไปยังอีกที่หนึ่ง เพื่อนำไปสร้างใหม่ และเพื่อเดินทางสู่อดีต” “หากเราดูสิ่งที่เราทำไปแล้ว เราใช้ Delphix เพื่อย้ายข้อมูลจากเซิร์ฟเวอร์ Exadata รุ่นเก่าไปยังเซิร์ฟเวอร์ Linux ของชุมชนเพื่อเพิ่มความสามารถในการปรับขนาดและใช้ต้นทุนต่ำลง”

Caseau กล่าวเสริมว่า “เรายังใช้ Delphix ในการเร่งนวัตกรรมและตั้งค่าสภาพแวดล้อมการทดสอบและการพัฒนาใหม่ให้เร็วขึ้น เราสามารถรับข้อมูลที่เหมาะสมทั้งหมดได้อย่างรวดเร็วด้วยพอยน์เตอร์เพียงไม่กี่ตัวและด้วยการคลิกเพียงแค่ไม่กี่ครั้ง อีกทั้งยังมีการถ่ายโอนข้อมูลเสมือนเมื่อเทียบกับข้อมูลที่มีอยู่จริง”

การจัดการข้อมูลการทดสอบเป็นองค์ประกอบที่สำคัญของการพัฒนาแอปพลิเคชัน แต่มักจะช้าและต้องทำด้วยตัวเอง แพลตฟอร์มข้อมูล Delphix DevOps ช่วยให้ทีมงานสามารถสร้าง จัดการ และทำให้สภาพแวดล้อมข้อมูลบนคลาวด์แบบไฮบริดเป็นแบบอัตโนมัติ เพื่อรองรับไปป์ไลน์ CI/CD และฝึกอัลกอริทึม AI/ML

Jim Mercer ผู้อำนวยการฝ่ายวิจัยของ DevOps และ DevSecOps ที่ IDC กล่าวว่า “ข้อมูลการทดสอบที่เป็นไปตามข้อกำหนดเป็นส่วนสำคัญของ DevOps และการทำให้มั่นใจว่าการเข้าถึงข้อมูลอย่างต่อเนื่องเป็นกุญแจสำคัญสำหรับองค์กรต่างๆ ในการเร่งการส่งมอบแอปพลิเคชัน” “เนื่องจากการเปลี่ยนผ่านสู่ดิจิทัลมีความจำเป็นมากขึ้นเรื่อย ๆ สำหรับองค์กรต่างๆ เพื่อแข่งขันในตลาดปัจจุบัน เราจึงยังคงเห็นถึงความต้องการโซลูชัน TDM ที่ทันสมัยในอุตสาหกรรมต่าง ๆ”

ไฮไลท์การเติบโตของ Delphix

Delphix ยังได้แนะนำนวัตกรรมหลายอย่างในการนำเสนอผลิตภัณฑ์ของบริษัทในปีงบประมาณที่แล้ว ได่แก่:

  • ห้องนิรภัยต่อเนื่องซึ่งเป็นความสามารถเฉพาะเพื่อแรนซัมแวร์ที่ช่วยเพิ่มความสามารถในการเก็บแยกข้อมูลจากกันของแพลตฟอร์ม Delphix และเสริมความแข็งแกร่งให้กับการปกป้องข้อมูลสำหรับองค์กร
  • ความสามารถในการปฏิบัติตามข้อมูลสำหรับลูกค้า Salesforceซึ่งช่วยปกป้องความเป็นส่วนตัวและความปลอดภัยของข้อมูลให้แก่ลูกค้า Salesforce ในขณะที่ยังช่วยปลดล็อกค่าในข้อมูล Salesforce ทั่วทั้งระบบคลาวด์และศูนย์ข้อมูลภายในองค์กร
  • หอควบคุมข้อมูลซึ่งให้จุดควบคุมเพียงจุดเดียวสำหรับระบบอัตโนมัติของข้อมูลการทดสอบที่ขับเคลื่อนด้วย API ทั่วทั้งไปป์ไลน์การพัฒนาตามขนาด
  • กำบังอัลกอริธึมสำหรับการปฏิบัติตามอย่างต่อเนื่องซึ่งนำเสนออัลกอริธึมระดับแนวหน้าของอุตสาหกรรมสำหรับการปกปิดข้อมูลที่ละเอียดอ่อนพร้อมกับ SDK ทำให้อัลกอริธึมที่กำหนดเองได้นั้นสามารถพัฒนาและดำเนินการได้อย่างอัตโนมัติ
  • การรวมระบบที่รับรองโดย SAP กับ SAP NetWeaver® และ SAP S/4HANA®ซึ่งช่วยให้ธุรกิจต่างๆ ใช้ Delphix เพื่อปกปิดและส่งข้อมูล SAP เสมือนจริงที่มีประสิทธิภาพผ่าน API ได้โดยอัตโนมัติ

เกี่ยวกับ Delphix

Delphix เป็นผู้นำในระบบอุตสาหกรรมการจัดเก็บข้อมูลการทดสอบ DevOps

ธุรกิจจำเป็นต้องเปลี่ยนรูปแบบการนำส่งแอปพลิเคชัน แต่ต้องใช้ความพยายามในการปรับความเร็วให้สมดุลกับการรักษาความปลอดภัยของข้อมูลและการปฏิบัติตามข้อบังคับ แพลตฟอร์มข้อมูล DevOps ของเราทำให้การรักษาความปลอดภัยข้อมูลเป็นแบบอัตโนมัติ ในขณะที่ปรับใช้ข้อมูลทดสอบอย่างรวดเร็วเพื่อเร่งการเปิดตัวแอปพลิเคชัน ด้วย Delphix ลูกค้าสามารถปรับแอปพลิเคชันให้ทันสมัย ปรับใช้มัลติคลาวด์ บรรลุ CI/CD และกู้คืนจากเหตุการณ์หยุดทำงาน เช่น แรนซัมแวร์ได้เร็วขึ้นสูงสุดถึง 2 เท่า

บริษัทชั้นนำ เช่น Choice Hotels, Banco Carrefour และ Fannie Mae ต่างก็ใช้ Delphix เพื่อเร่งการเปลี่ยนแปลงทางดิจิทัลและเปิดใช้งานการจัดการข้อมูลแบบ Zero trust เยี่ยมชมเราได้ที่ www.delphix.com ติดตามเราได้ที่ ลิงกต์อินทวิตเตอร์ และ เฟซบุ๊ก 

Josh Harbert

ประธานเจ้าหน้าที่ฝ่ายการตลาด                |        Delphix

913.972.6180

Philips successfully prices offering of Notes for EUR 2 billion

April 28, 2022

THIS ANNOUNCEMENT IS FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER OR INVITATION TO SELL, OR ANY SOLICITATION OF AN OFFER TO PURCHASE, ANY SECURITIES OF PHILIPS.

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the successful pricing of its issue of EUR 750 million fixed rate notes due 2027 (“2027 Notes”), EUR 650 million Green Innovation Notes due 2029 and EUR 600 million Sustainability Innovation Notes due 2033 (together, the “Notes”) under its European Medium Term Note (EMTN) program (the “EMTN Offering”).

The net proceeds of the Notes will be used for Eligible Projects in accordance with Philips Green and Sustainability Innovation Bond Framework and, in the case of the 2027 Notes, for general corporate purposes. Pending the full allocation of the net proceeds of the Notes, Philips intends to optimize its short-term treasury liquidity profile by applying such net proceeds towards the following liability management transactions which were announced earlier today, all of which are subject to the successful completion of the EMTN Offering:

  • A tender offer for certain series of its outstanding U.S. Dollar-denominated bonds due 2025 and 2026;
  • A tender offer for certain series of its outstanding Euro-denominated notes due 2023, 2024 and 2025 (the “Euro Tender Offer”);
  • The proposed make-whole redemption of any of the Euro-denominated notes due 2023 and 2024 that are not purchased in the Euro Tender Offer (the “Euro Make-Whole Redemption”); and
  • The proposed agreement with the relevant counterparties for early settlement of the outstanding forward contracts entered into in the third quarter of 2021 under the share buyback program for capital reduction purposes announced on July 26, 2021 (the “Early Forward Settlement”). The acquisition of 19,571,218 shares through the settlement of these forward contracts would result in the early completion of the repurchase program. Philips would then expect to cancel a total of approximately 28.3 million shares (including shares acquired through open market purchases in December 2021 and January 2022 under the aforementioned share buyback program) in the course of 2022, representing 3.3% of Philips’ currently outstanding shares.

Any decision by Philips to redeem outstanding bonds in the Euro Make-Whole Redemptions, or to complete the Early Forward Settlement, will depend on various factors at that time.

The issue price for the 2027 Notes is 99.458% with a Coupon of 1.875%, resulting in a yield of 1.990%. The issue price for the Green Innovation Notes is 99.165% with a Coupon of 2.125%, resulting in a yield of 2.248%. The issue price for the Sustainability Innovation Notes is 99.473% with a Coupon of 2.625%, resulting in a yield of 2.681%.

Settlement and issue of the Notes is scheduled for 5 May 2022. Application has been made for the Notes to be listed on the Official List of the Luxembourg Stock Exchange and to trading on the regulated market of the Luxembourg Stock Exchange.

For further information, please contact:

Ben Zwirs
Philips Global Press Office
Tel.: +31 6 1521 3446
E-mail: ben.zwirs@philips.com

Derya Guzel
Philips Investor Relations
Tel.: +31 20 5977055
E-mail: derya.guzel@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2 billion and employs approximately 78,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Forward-looking statements
This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the EMTN Offering, the USD Tender Offer, the Euro Tender Offer, the Euro Make-Whole Redemption and the Early Forward Settlement. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

Important Information
This announcement is for informational purposes only and does not constitute or form part of any offer or invitation to sell, or any solicitation of an offer to purchase, any securities of Philips.  The securities offered in the EMTN Offering have not been and will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.  Neither the EMTN Offering nor the Euro Tender Offer is being made and will not be made directly or indirectly in or into, or by use of the mails of, or by any means or instrumentality (including, without limitation, facsimile transmission, telex, telephone, email and other forms of electronic transmission) of interstate or foreign commerce of, or any facility of a national securities exchange of, or to owners of the subject securities who are located or resident in the United States or to U.S. Persons as defined in Regulation S of the Securities Act.

In the United Kingdom, this announcement is being distributed to, and is directed at, only (a) persons who have professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”); or (b) high net worth companies, and other persons to whom it may otherwise lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). The Notes are available only to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such Notes will be available only to or will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this announcement or any of its contents.

Manufacturer target market (MIFID II and UK MiFIR product governance) is eligible counterparties and professional clients only (all distribution channels). No PRIIPs or UK PRIIPs key information document (KID) has been prepared as not available to retail in EEA or UK.

Bombardier to Report First Quarter 2022 Financial Results and Hold Virtual Annual and Special Meeting of Shareholders on Thursday, May 5, 2022

MONTREAL, April 28, 2022 (GLOBE NEWSWIRE) — Bombardier (TSX: BBD.B) will publish its financial results for the first quarter of 2022 on May 5, 2022. On the same day, Bombardier will hold its Annual and Special Meeting of Shareholders (“Meeting”) in a virtual format.

Quarterly Conference Call

On May 5, 2022, at 8:00 a.m. EDT, Bombardier will hold a webcast/conference call intended for investors and financial analysts to review the company’s financial results for the first quarter ended March 31, 2022.

A live webcast of the call and relevant financial charts will be available at https://ir.bombardier.com

Stakeholders wishing to listen to the presentation and subsequent question-and-answer period by telephone may dial one of the following conference call numbers:

In English:

Toll-free dial-in number (Canada/U.S.): 1-800-898-3989
Local dial-in number: 514-861-3304
International dial-in numbers

Participant passcode: 2230833#

In French (with translation):
Toll-free dial-in number (Canada/U.S.): 1-877-395-0279
Local dial-in number: 514-392-1587
International dial-in numbers

Participant passcode: 4427560#

Media Call

May 5, 2022, at 9:30 a.m. EDT, members of the media are invited to dial in to a short Question and Answer session following our quarterly earnings call and before the virtual Annual and Special Meeting of Shareholders. Éric Martel, President and Chief Executive Officer of Bombardier, will be available to answer your questions related to the Q1 2022 financial results.

Media who would like to attend the Q&A session are asked to RSVP by emailing heather.neale@aero.bombardier.com.

Bilingual:

Toll-free dial-in number (Canada/U.S.): 1-800-952-5114
Local dial-in number: 416-406-0743
International dial-in numbers

Participant passcode: 2423914#

Annual and Special Meeting of Shareholders

On May 5, 2022, at 10:30 a.m. EDT, Bombardier welcomes all registered shareholders and duly appointed proxyholders who wish to participate in the online Meeting to do so by joining the live webcast available at https://bombardier.com/en/agm2022. Only registered shareholders and duly appointed proxyholders will be allowed to vote and ask questions during the live Meeting. Non-registered shareholders, guests and media will be able to watch online via the live webcast available at the same link.

Instructions on how to vote and participate in the online Meeting, including submitting questions to management and to the Chairman of the Board of Directors of Bombardier, will be available on the Corporation’s website here and on the online Meeting platform. Bombardier encourages shareholders to vote and submit their proxies prior to the Meeting.

The live webcast and relevant documents for both the Annual and Special Meeting of Shareholders and the conference call will be available at https://bombardier.com/en/agm2022. A recording of the Meeting and the call will be posted on Bombardier’s website shortly after the end of the webcast.

About Bombardier
Bombardier is a global leader in aviation, focused on designing, manufacturing and servicing the world’s most exceptional business jets. Bombardier’s Challenger and Global aircraft families are renowned for their cutting-edge innovation, cabin design, performance and reliability. Bombardier has a worldwide fleet of approximately 5,000 aircraft in service with a wide variety of multinational corporations, charter and fractional ownership providers, governments and private individuals. Bombardier aircraft are also trusted around the world in special-mission roles.

Headquartered in Montréal, Québec, Bombardier operates aerostructure, assembly and completion facilities in Canada, the United States and Mexico. The company’s robust customer support network includes facilities in strategic locations in the United States and Canada, as well as in the United Kingdom, Germany, France, Switzerland, Italy, Austria, the UAE, Singapore, China and an Australian facility opening in 2022.

For corporate news and information, including Bombardier’s Environmental, Social and Governance report, visit bombardier.com. Learn more about Bombardier’s industry-leading products and customer service network at businessaircraft.bombardier.com. Follow us on Twitter @Bombardier.

Bombardier is a registered trademark of Bombardier Inc. or its subsidiaries.

For Information

Francis Richer de La Flèche
Vice President
Financial Planning and Investor Relations
Bombardier
+514 855 5001 x13228
Anna Cristofaro
Manager
Communications
Bombardier
+1 514 855 8678

CORONAVIRUS/Taiwan expected to buy 30 million COVID-19 saliva rapid tests

Taiwan is expected to import up to 30 million home-use self-tests that can detect the COVID-19 virus in saliva after the country’s Food and Drug Administration (FDA) approved the move Friday.

The tests, all of the same brand made in South Korea, will be labeled with Chinese characters and packaged with Chinese instructions before being sold in Taiwan, the FDA said.

The Gmate COVID-19 Ag Saliva, as the test is called, will be the first saliva COVID-19 rapid test approved for home use in Taiwan.

The test is currently also sold in Australia and has a sensitivity of 95.83 percent and specificity of 99.6 percent compared to PCR tests, according to testing conducted in Taiwan, the FDA said.

Import approved by Taiwan FDA

A total of 30 million tests are expected to be imported after an application to import the tests was approved on Friday, the FDA said.

Applications to import other home-use saliva rapid tests are also being processed, while domestically made tests are being evaluated for home use, the FDA said.

The move to import the tests came after Minister of Health and Welfare Chen Shih-chung (???) said earlier on Friday that Taiwan will likely approve the purchase of a home-use self-test that can detect the COVID-19 virus in saliva.

The less invasive and easier to administer test is being reviewed out of consideration for children and other groups who find nasal swabs difficult, Chen said at a daily COVID-19 press conference.

Lawmakers’ call

Multiple lawmakers have also urged the government to import rapid saliva tests, including ruling Democratic Progressive Party lawmaker Kao Chia-yu (???) and New Power Party legislators Chiu Hsien-chih (???) and Claire Wang (???).

Wang said allowing the use of saliva self-tests will boost COVID-19 testing resources in Taiwan.

If Taiwan is moving in the direction of living with the virus, rapid testing procedures need to be simplified, Wang said.

Compared to rapid tests which require the insertion of a swab deep into the nose, the saliva test is less invasive, Wang added.

In addition, people may be hesitant to keep going for nasal swab tests if they previously had a bad experience, Wang added.

Source : Focus Taiwan News Channel

Taiwan delays permanent residency plan for HK, Macau professionals

Taiwan has put on hold a plan to allow professionals from Hong Kong and Macau to apply for permanent residency after at least five years on a work permit, an official said Friday, citing security concerns.

The new immigration rule, which was set to be implemented on May 1, requires further review and public discussion, Mainland Affairs Council (MAC) spokesperson Chiu Chui-cheng (???) told CNA in a telephone interview.

He said lawmakers had expressed concern over national security issues, most recently at a legislative hearing on Thursday.

During the hearing, Legislator Chen Jiau-hua (???) of the New Power Party asked if the government had a mechanism to prevent hostile infiltration by individuals who are granted permanent residency in Taiwan under the new rule.

In response, MAC Deputy Minister Lee Li-jane (???) said that such individuals would be monitored jointly by the MAC, the Ministry of the Interior, the National Development Council and the National Security Bureau.

Legislator Wang Ting-yu (???) of the ruling Democratic Progressive Party (DPP) said at the hearing that while he supported the plan to attract more overseas talent and help Hong Kong democracy advocates, Taiwan has to be cautious in the face of the growing threat posed by China.

The residency policy was announced on April 21 by Chiu, who expected the National Immigration Agency would formally introduced a regulation amended for the policy on May 1 with immediate effect.

Under the revisions, Taiwan’s current permanent residency policy regarding people from Hong Kong and Macau was to be expanded to cover those who have held a work permit in Taiwan for at least five years and had earned at least double the minimum wage in the fifth year.

Currently, people from Hong Kong and Macau are eligible to apply for permanent residency if they have relatives in Taiwan, make government-recognized contributions, are entrepreneurs in certain innovative businesses, or have specific skills, technologies or experience.

Hong and Macau residents who graduate from Taiwan universities can also apply for permanent residence after five years on a work permit, with monthly earnings of at least double the minimum wage in the fifth year, according to the current regulations.

Chiu said Friday that while the new expanded plan had been discussed with lawmakers and civic groups, the government has decided to delay its implementation, pending further consultations and a wider consensus.

Source : Focus Taiwan News Channel

Informa Pharma Intelligence and The American Society of Gene & Cell Therapy (ASGCT) Launches Gene, Cell & RNA Therapy Landscape Q1 2022 Quarterly Data Report

New Report Highlights Key Industry Trends in Pharmaceutical R&D

NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) — Informa Pharma Intelligence, the global business intelligence provider for the biopharma industry, and The American Society of Gene & Cell Therapy (ASGCT), today announced the launch of the Gene, Cell & RNA Therapy Landscape Q1 2022 Quarterly Data Report. The Q1 2022 report assesses industry trends by examining approved gene, cell and RNA therapies, the pharmaceutical pipeline by company, most targeted therapeutic areas, and an overview of recent dealmaking and start-up funding.

Notable findings from the first quarterly report of the year include:

  • FDA Approvals – Since Q4 2021, one new genetically modified cell therapy has been approved and one new gene therapy has filed for approval. Carvykti, a CAR-T cell therapy developed by Legend Biotech and Johnson & Johnson, was approved for multiple myeloma in the U.S. and EtranaDez (etranacogene dezaparvovec), an AAV5 gene therapy developed by uniQure, was filed for approval in the EU and UK for hemophilia B.
  • Gene Therapy Pipeline Growth  Since Q1 2021, the gene therapy pipeline has increased by 16% with 3,579 therapies in development, ranging from preclinical through preregistration. A total of 1,986 gene therapies (including genetically modified cell therapies such as CAR T-cell therapies) are in development, accounting for 55% of gene, cell and RNA therapies; and 816 non-genetically modified cell therapies are in development, accounting for 22% of gene, cell and RNA therapies.
  • Most Targeted Therapeutic Areas  Oncology and rare diseases continue to be the top areas of gene therapy development in both the overall pipeline (preclinical to preregistration) and in the clinic (Phase I to preregistration). Development for rare diseases most commonly occurs in the oncology space, representing a majority of 52% compared to non-oncology rare disease gene therapy pipeline development.
  • Deal Making – A total of 123 deals were signed, a 15% decrease in volume from Q4 2021. Q1 2022 was the lowest quarter total within the last year, and acquisition and alliance volume quarter by quarter remained flat, while financings continue to trend down. Acquisitions were the only type of deal to increase in Q1 2022.
  • Start-up Financing – Start-up financing by gene, cell and RNA therapeutic companies remained steady in Q1 2022. A total of 15 companies raised seed or Series A financing, totaling an aggregate $507.8M. The overall deal-making total across alliance, acquisitions and financings saw a 15% decline. In the largest start-up financing, Cellino Biotech, a Harvard University spin-out, raised $80M to support its large-scale production of autologous and allogeneic cell therapies.

“Since we started putting these quarterly reports together in Q1 2021, we have seen the gene therapy pipeline steadily increase. Oncology and rare disease remain the most targeted therapeutic areas, and we continue to see a strong pipeline for CAR-T cell therapies for cancer indications,” said Ly Nguyen-Jatkoe, PhD, Executive Director, Americas, Informa Pharma Intelligence. “Rare diseases continue to be a focus for RNA therapies.”

“The continued approvals of gene and cell therapies has turned into one of the brightest spots in releasing this report each quarter,” said David Barrett, JD, CEO, the American Society of Gene & Cell Therapy (ASGCT). “With the approval of Carvykti in Q1 2022 and the ever-expanding pipeline, we’re exceptionally optimistic about the future of the field.”

All pipeline and trial insights were compiled using data from Pharma Intelligence’s Pharmaprojects™, and Trialtrove™, part of Citeline, which has been tracking global drug development since 1980. Deal, financing and catalyst data were derived from Biomedtracker™. For more information, or to view the current and past reports, visit Informa Pharma Intelligence or contact pharma@informa.com.

About The American Society of Gene & Cell Therapy (ASGCT)
The American Society of Gene & Cell Therapy (ASGCT) is the primary professional membership organization for scientists, physicians, patient advocates and other professionals with interest in gene and cell therapy.

Our members work in a wide range of settings including universities, hospitals, government agencies, foundations, biotechnology and pharmaceutical companies. ASGCT advances knowledge, awareness and education leading to the discovery and clinical application of gene and cell therapies to alleviate human disease to benefit patients and society.

About Informa Pharma Intelligence
Informa Pharma Intelligence powers a full suite of analysis products — Datamonitor Healthcare™, Sitetrove™, Trialtrove™, Pharmaprojects™, Biomedtracker™, Scrip™, Pink Sheet™ and In Vivo™ — to deliver the data needed by the pharmaceutical and biomedical industry to make decisions and create real-world opportunities for growth.

With more than 400 analysts keeping their fingers on the pulse of the industry, no key disease, clinical trial, drug approval or R&D project isn’t covered through the breadth and depth of data available to customers. For more information, visit pharmaintelligence.informa.com

Media Contacts:
Diffusion PR for Informa Pharma Intelligence
informapharma@diffusionpr.com

Alex Wendland for The American Society of Gene & Cell Therapy (ASGCT)
AWendland@asgct.org

Delphix Accelerates Growth, Profitability for Second Consecutive Year at Scale

Data Security, Compliance Drive Urgent Adoption of Delphix DevOps Test Data Management Platform

REDWOOD CITY, Calif., April 28, 2022 (GLOBE NEWSWIRE) — Delphix, the industry leader in DevOps test data management (TDM), today announced closing fiscal year 2022 with a second consecutive year of accelerated revenue growth and profitability at a scale well over $100M in annual recurring revenue (ARR).

With increasing activity from hostile nation states and ransomware gangs, companies around the world need a solution to automate and secure test data for enterprise applications. As a result, the company also reported 36% faster year-over-year growth of its large, enterprise customer base driven by increasing data risks.

Delphix’s growth comes as companies around the world continue to invest in innovative DevOps solutions to accelerate application delivery, modernize legacy infrastructure, and move applications across the multicloud. Delphix offers the only DevOps TDM platform that automates the delivery of secure, compliant data for test and development, enabling up to 10x faster innovation.

“Enterprise applications all need test data for fast, quality releases,” said Jedidiah Yueh, Delphix Founder and CEO. “But test data has traditionally been slow, complex, and filled with risk. Delphix helps companies like Banco Carrefour, The University of Manchester, and BNP Paribas release applications quickly while improving data security and compliance.”

Banco Carrefour in Brazil utilizes the Delphix DevOps Data Platform to accelerate application releases while ensuring data security and compliance with privacy regulations such as Brazil’s General Data Protection Law (LGPD). Delphix empowers development teams with 320x faster data availability for financial reporting and analytics, enables faster application releases, and helps save 70% on storage.

Delphix delivers an innovative API-first data platform that transforms application delivery with comprehensive data controls. By automating data delivery into test environments, Delphix helps software developers innovate faster while reducing compliance and security risk.

Delphix also helps companies recover faster from ransomware attacks by continuously protecting data and making historical data immutable.

“We selected Delphix, because we like the technology as a tool to move data efficiently from one place to another, to reconstruct, to travel to the past,” said Yves Caseau, Group Chief Digital & Information Officer at Michelin. “If we look at what we’ve done, we used Delphix to move data from our Exadata server legacy to community Linux servers to get more scalability and lower cost.”

“We are also using Delphix as a way to accelerate innovation and set up new test and development environments faster. We can get all the appropriate data very fast with a few pointers and a few clicks and have a virtual transfer of the data as opposed to a physical one,” Caseau added.

Test data management is a critical component of application development but is often slow and manual. The Delphix DevOps Data Platform enables teams to create, manage, and automate hybrid cloud-based data environments to support CI/CD pipelines and train AI/ML algorithms.

“Compliant test data is the lifeblood of DevOps and ensuring continuous access to it is key for enterprises to accelerate application delivery,” said Jim Mercer, Research Director of DevOps and DevSecOps at IDC. “With digital transformation becoming increasingly essential for enterprises to compete across today’s marketplaces, we continue to see the need for modern TDM solutions across multiple industries.”

Delphix Growth Highlights

Delphix also introduced multiple innovations across the company’s product offerings in last fiscal year, including:

About Delphix

Delphix is the industry leader for DevOps test data management.

Businesses need to transform application delivery but struggle to balance speed with data security and compliance. Our DevOps Data Platform automates data security, while rapidly deploying test data to accelerate application releases. With Delphix, customers modernize applications, adopt multi-cloud, achieve CI/CD, and recover from downtime events such as ransomware up to 2x faster.

Leading companies, including Choice Hotels, Banco Carrefour, and Fannie Mae, use Delphix to accelerate digital transformation and enable zero trust data management. Visit us at www.delphix.com. Follow us on LinkedIn, Twitter, and Facebook.


Josh Harbert     
Chief Marketing Officer   |   Delphix
913.972.6180

MMEX RESOURCES CORP. AND THE PROVINCE OF TIERRA DEL FUEGO ARGENTINA JOINTLY ANNOUNCE THE POTENTIAL DEVELOPMENT OF A GREEN HYDROGEN PROJECT FROM WIND POWER IN RÍO GRANDE, PROVINCE OF TIERRA DEL FUEGO, ARGENTINA

FORT STOCKTON, TEXAS, April 28, 2022 (GLOBE NEWSWIRE) — Today, the Province of Tierra del Fuego and MMEX jointly announce the potential development of a green hydrogen project in the Río Grande area.

The Governor of the Province of Tierra del Fuego, Mr. Gustavo Adrian Melella, announced that, “MMEX, a North American company with operations in Texas USA with extensive experience in the implementation, financing and operation of energy infrastructure in Latin America and the USA, is evaluating a project for the production of 55 tons of green hydrogen with 160 megawatts of base wind power.”

Governor Melella added, “The excellent wind conditions in the Río Grande area, which allow efficient logistics and production and direct access to the sea, are the basis for MMEX’s entry into Argentine Patagonia. The final objective would be the implementation of a green hydrogen node destined to export to Europe and Asia. We welcome and support the participation of MMEX in Tierra del Fuego.”

Jack W. Hanks, the CEO of MMEX stated, “We are very excited to join the Government of Tierra del Fuego to plan this project. The global focus on renewable energy and the need to reduce the planet’s carbon footprint is at the core of Tierra del Fuego and MMEX’s strategy, drawing on MMEX’s green hydrogen expertise.”

Hanks added, “Since 1989, in Texas and Peru, MMEX has built and operated thermoelectric plants, oil and gas pipelines, oil refineries and ethanol plants. It has also explored and operated oil and gas fields. MMEX, in conjunction with Siemens Energy, recently completed a front-end engineering design study for the production of 55 tons per day of hydrogen for this project and its other projects in Texas. Hydrogen can be transformed into Ammonia or Methanol for global exports. It is estimated that the investment will be in the range of US $500 million, generating up to 1,500 jobs in the construction stage and 300 qualified and permanent jobs in the operation stage.”

Hanks further commented, “Siemens Energy is a leading manufacturer of electrolysis equipment that enables the transition to clean energy. MMEX has also signed a memorandum of understanding with Siemens Energy and Siemens Gamesa, one of the world leaders in the production of wind towers, which is associated with the realization of this project. This will allow defining the necessary wind turbine and the required land to implement a 160MW wind farm that supplies electrical energy to the Siemens electrolysers to produce hydrogen.”

Governor Melella added, “The province of Tierra del Fuego and MMEX have signed agreements on the exchange of technical information. This allows rapid progress in the preliminary assessment of wind potential.”

The provincial government, within its support for the development of renewable energy industries, welcomes initiatives that allow the sustainable use of Tierra del Fuego’s resources and reaffirms, as a government, its commitment to sustainable development, the preservation of the environment, investment and employment.

The following constitutes a “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, which could cause our actual results to differ materially from those described in the forward looking statements. These risks include but are not limited to the Company’s ability to continue as a going concern, our lack of revenues, general business conditions, the requirement to obtain significant financing to pursue our business plan, our history of operating losses and other risks detailed from time to time in the Company’s SEC reports. In particular, readers should note MMEX undertakes no obligation to update forward-looking statements.

Kristen Quinn
MMEX Resources Corporation
kristen@paigepr.com

Philips and Prisma Health sign multi-year, long-term strategic partnership to innovate healthcare across the enterprise and unlock the power of patient data

April 28, 2022

South Carolina’s largest health system adopts Philips software solutions for patient monitoring and enterprise imaging, helping to drive interoperability and data analytics, and deliver on Quadruple Aim

Amsterdam, the Netherlands and South Carolina, USA – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Prisma Health, South Carolina’s largest non-profit healthcare system, today announced they have entered into a multi-year agreement to help the health system achieve enterprise interoperability, standardize patient monitoring, and drive innovation in enterprise imaging solutions to enhance patient care and improve clinical performance. As South Carolina’s largest private, non-profit healthcare system, and second-largest private company, Prisma Health wants to deliver on the quadruple aim: improve patient and staff satisfaction, lower costs, and improve outcomes for all South Carolinians.

Prisma Health was formed in 2017 when Greenville Health System and Palmetto Health, two of South Carolina’s most highly regarded healthcare systems, came together as one organization. Today, Prisma Health has nearly 3,000 licensed beds and 18 acute care and specialty hospitals, as well as 270 physician practices servicing 21 counties. They treat over one million unique patients across their networks each year, including 368,000 virtual care visits, and just under half a million emergency department visits.

“When our two regional healthcare organizations merged, an enterprise-wide technology strategy became critical to standardize best practices across the whole system, creating new bridges between hospital and home care and continuing to drive innovation,” said Rich Rogers, Senior Vice President, Chief Information Officer, Prisma Health.  “At Prisma Health, we wanted to engage a partner to help us address data integration and unlock the power of patient data so that we are able to provide our patients with the best care anywhere in our service areas. We want to put the right tools into the hands of our clinicians to allow them to better share information, collaborate and help transform care for the communities we serve.”

With the Philips HealthSuite secure cloud platform at its foundation, Philips is committed to enterprise interoperability. Philips’ solutions portfolio includes real-time patient monitoring, therapeutic devices, telehealth, image management and informatics solutions including radiology and cardiology PACS, advanced visualization, vendor neutral archive (VNA) and Philips Enterprise Viewer – Vue Motion, and interoperability solutions, including the industry-leading Philips Capsule Medical Device Information Platform. Prisma Health will not only have access to these technologies, they will also be the largest installation of the Philips Enterprise Performance Analytics – Performance Bridge – analytics platform in North America. Performance Bridge gives healthcare professionals access to near real-time data on departmental performance through an easy-to-use interactive dashboard. Vendor agnostic, Performance Bridge unifies information across different imaging modalities and informatics solutions to optimize organizational efficiency, drive adherence to standards of care and facilitates additional revenue streams. Prisma Health plans to use Performance Bridge to drive innovation and monitor their delivery of quality healthcare.

“At Philips, we made a deliberate decision to create an end-to-end enterprise strategy that will help our customers overcome interoperability barriers and enable data sharing,” said Vitor Rocha, Chief Market Leader for Philips North America. “Health systems shouldn’t have to worry about integrating technology, which is why we have developed vendor-agnostic solutions based on standards and frameworks that bring together data from applications, systems, and devices. This allows our partners to focus on what is most important to them and their patients – continuously improving the patient journey and outcomes.”

Long-term strategic partnerships (LSPs) are a growing trend within hospitals and health systems to better manage the cost and complexity of their technology investments over a defined period of time, while expanding quality access to advanced medical care to improve patient outcomes. Philips is a leader in LSPs and continues to work with forward-thinking organizations like Prisma Health to develop standards, best practices, and predictive technologies that can redefine the future of healthcare.

For further information, please contact:

Mark Groves
Philips Global Press Office
Tel.: +31 631 639 916
E-mail: mark.groves@philips.com

Silvie Casanova
Philips North America
Tel.: +1 781 879 0692
E-mail: silvie.casanova@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2 billion and employs approximately 78,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

About Prisma Health
Prisma Health is a non-profit health company and the largest healthcare system in South Carolina. With nearly 30,000 team members, 18 acute and specialty hospitals, 2,947 beds and more than 300 outpatient sites with nearly 2,000 physicians, Prisma Health serves more than 1.5 million unique patients annually in its 21-county market area that covers 50% of South Carolina. Prisma Health’s goal is to improve the health of all South Carolinians by enhancing clinical quality, the patient experience and access to affordable care, as well as conducting clinical research and training the next generation of medical professionals. Visit PrismaHealth.org for more information.

Attachment

Leading Supply Chain Visibility Platform FourKites Awarded ISO 27001 Certification and Meets Standards for ISO 27017 and 27018

Enterprise-grade cloud security and data privacy gives FourKites customers and partners additional peace of mind

FourKites Awarded ISO 27001 Certification and Meets Standards for ISO 27017 and 27018

Enterprise-grade cloud security and data privacy gives FourKites customers and partners additional peace of mind

CHICAGO, April 28, 2022 (GLOBE NEWSWIRE) — Leading real-time supply chain visibility platform FourKites® today announced it meets the standards set by the International Standards Organization (ISO) for ISO 27017 for cloud service security and ISO 27018 for data privacy as part of its ISO 27001 certification. The achievement represents FourKites’ ongoing pursuit of the most recent and stringent security standards in the industry.

To qualify, an independent audit committee confirmed that FourKites meets a stringent set of requirements around security and privacy. ISO 27017 provides guidelines for information security controls applicable to and specific to the provisioning and use of cloud services, while ISO 27018 establishes commonly accepted controls and guidelines for implementing measures to protect personally identifiable information (PII) for the public cloud computing environment. Meanwhile, ISO 27001 mandates controls for the establishment, maintenance and certification of an information security management system (ISMS).

“Meeting these standards is a testament to FourKites’ ongoing commitment to go above and beyond when it comes to securing our platform, which ingests more than 250 terabytes of data each month,” said Mathew Elenjickal, FourKites Founder and CEO. “Safe and secure data sharing has tremendous benefits across the supply chain, including more accurate business planning and risk mitigation, higher customer satisfaction and retention, and improved employee morale.”

Adherence to ISO 27017 and 27018 is the latest validation of FourKites’ rigorous security efforts, including its comprehensive General Data Protection Regulation (GDPR) privacy program, which even applies in regions where it is not required and incorporates the Schrems II ruling.

“Our supply chain customers and partners around the globe can rest assured that FourKites uses the strongest and most secure standards in the industry to protect their valuable data,” added Elenjickal.

FourKites delivers real-time insights to customers around the globe, leveraging patented artificial intelligence based on 150 factors, including ​​weather, traffic and real-time data from GPS, ELD telematics networks, mobile devices, AIS and more. The company offers out-of-the-box dashboards and reports, automated and customizable notifications that leverage geofencing and temperature tracking, and SKU-level visibility to track multimodal shipments, even when they’re split across multiple carriers.

In Spring 2021, FourKites was awarded a patent for its groundbreaking Smart Forecasted Arrival (SFA) solution, which provides companies with highly frequent and accurate estimated times of arrival for over-the-road freight in transit — even when a truck lacks any technology to transmit location data. SFA is now available to FourKites customers globally, extending the benefits of real-time visibility to freight that would otherwise be invisible to modern supply chain management solutions.

About FourKites
FourKites® is the #1 global supply chain visibility platform, extending visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 2.5 million shipments daily across road, rail, ocean, air, parcel and courier, and reaching more than 185 countries, FourKites combines real-time data and powerful machine learning to help companies digitize their end-to-end supply chains. More than 1,000 of the world’s most recognized brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.

Media Contacts
Marianna Vyridi
Big Valley Marketing for FourKites
(650) 468-3263
mvyridi@bigvalley.co

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5ed752ac-3bf9-4eaf-bb8b-e08ba31b326d


Copyright © 2022 GlobeNewswire, Inc.